This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on ISI (1)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • HIV/AIDS  • Pediatrics  • Neonatology and Infant Care  • Alert me on articles by topic

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor: The time at which antiretroviral therapy (ART) should be initiated in children with perinatal human immunodeficiency virus (HIV) infection remains controversial. In a cohort study, Berk et al¹ reported clinical benefit from mono/dual ART started before 60 days of life in 10 children compared with treatment administered at 61 to 120 days of life in 16 children. The 23 children who received early triple ART were not investigated because none of them progressed to category C diagnosis by 3 years of age. We performed a similar analysis in a cohort study of a larger data set of children with a longer follow-up to evaluate the outcomes of early and very early triple ART.

Methods

This was a post hoc analysis of data collected by the Italian Register for HIV Infection in Children, a network of 106 pediatric clinics distributed throughout Italy that is highly representative of the Italian . . . [Full Text of this Article]

Elena Chiappini, MD, PhD; Luisa Galli, MD
Department of Pediatrics
University of Florence
Florence, Italy

Clara Gabiano, MD; Pier-Angelo Tovo, MD
Department of Pediatrics
University of Turin
Turin, Italy

Maurizio de Martino, MD
maurizio.demartino@unifi.it
Department of Pediatrics
University of Florence
Florence, Italy
For the Italian Register for HIV Infection in Children